Pharmacogenomics in medication-related osteonecrosis of the jaw: a systematic literature review

N Bastida-Lertxundi1, I O Leizaola-Cardesa, J Hernando-Vázquez

  • 1Department of Genetics, Donostia University Hospital, San Sebastian, Spain. ggomez@ugr.es.

Abstract

Insights

Genetic factors moderately impact medication-related osteonecrosis of the jaw (ONJ). While studies found associations with single nucleotide polymorphisms (SNPs), further research with larger sample sizes is needed to clarify genetic contributions to ONJ.

Area of Science:

  • Genetics
  • Pharmacology
  • Oral Medicine

Background:

  • Medication-related osteonecrosis of the jaw (ONJ) is a severe adverse effect linked to bisphosphonates, antiresorptive, and antiangiogenic drugs.
  • The exact causes of ONJ are unknown, but genetic factors are suspected.
  • ONJ affects patients with osteoporosis or neoplasms.

Purpose of the Study:

  • To review existing literature on genetic factors associated with ONJ.
  • To synthesize findings from case-control studies investigating genetic predispositions to ONJ.

Main Methods:

  • A systematic review of articles published between 2008 and 2018.
  • Inclusion of fifteen case-control studies focusing on genetic factors in ONJ.
  • Analysis of studies using genome-centered and gene-centered approaches.

Main Results:

  • Nine out of fifteen studies identified statistically significant associations between single nucleotide polymorphisms (SNPs) and ONJ.
  • Studies employed diverse genetic techniques, including genome-centered and gene-centered variant investigations.
  • No consensus was reached among studies regarding specific genes linked to ONJ.

Conclusions:

  • Genetic factors appear to have a moderate influence on the development of ONJ.
  • Significant heterogeneity exists in current research methodologies and findings.
  • Future research necessitates international collaboration for larger sample sizes and robust study designs to advance ONJ understanding and patient risk stratification.

Related Concept Videos

Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
157
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
154
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
168
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
183
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
3.8K
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
202